Context:
An editorial highlights that India’s pharmaceutical industry—often called the “pharmacy of the world” — must transition from high-volume generic drug production to value-driven innovation to achieve the ambitious $350 billion pharmaceutical export target by 2047.
Key Highlights:
India as the ‘Pharmacy of the World’
- India currently produces around 60% of the world’s vaccines and medicines in various segments.
- The industry has helped save patients over $2 trillion globally in the past decade by supplying affordable generic medicines.
- Indian pharmaceutical firms are major suppliers of low-cost medicines to both developed and developing countries.
Historical Policy Foundations
- Patents Act, 1970
- Replaced product patents with process patents for pharmaceuticals.
- Enabled Indian companies to reverse-engineer drugs and produce affordable generics.
- Played a key role in building India’s generic drug industry.
- Hatch-Waxman Act (1984) – United States
- Created a regulatory framework to facilitate approval of generic drugs.
- Encouraged competition between branded and generic medicines, reducing costs.
- Resulted in generic drugs constituting around 90% of prescriptions in the US today.
Need to Shift from Volume to Value
- India currently dominates generic drug manufacturing, which is volume-driven and low-margin.
- Future growth depends on:
- Innovation-driven pharmaceuticals
- Biotechnology and advanced therapies
- High-value patented drugs
- The industry must focus on research, intellectual property, and high-end manufacturing capabilities.
Challenges Facing the Sector
- Low investment in pharmaceutical R&D
- Regulatory bottlenecks
- Limited university-industry collaboration
- Dependence on imported Active Pharmaceutical Ingredients (APIs)
Global Competition
- Countries such as China have strengthened their pharmaceutical sector through:
- Strong government–industry–academic collaboration
- Large investments in science and technology
- Integrated industrial policy frameworks.
Strategic Importance
- Pharmaceutical strength contributes to:
- Economic growth
- Technological advancement
- Geopolitical influence
- Health security
Relevant Prelims Points:
- Generic Drugs
- Medicines equivalent to brand-name drugs in dosage, safety, and efficacy.
- Produced after patent expiry of original drugs.
- Generally much cheaper due to competition.
- Process Patent
- A patent granted for a method of manufacturing a product, not the product itself.
- Allows other manufacturers to produce the same product using different processes.
- Product Patent
- Protects the actual product or molecule, preventing others from manufacturing it.
- TRIPS Agreement (WTO)
- Agreement on Trade-Related Aspects of Intellectual Property Rights.
- Requires countries to recognise product patents, which India adopted in 2005.
- Hatch-Waxman Act (1984)
- Officially known as the Drug Price Competition and Patent Term Restoration Act.
- Simplified the approval process for generic drugs in the US.
Relevant Mains Points:
Importance of the Indian Pharmaceutical Industry
- India is the third-largest pharmaceutical producer by volume globally.
- Supplies low-cost medicines to over 200 countries.
- Plays a key role in global public health and vaccine supply chains.
Challenges in Transitioning to Value-Based Growth
- Low R&D expenditure compared to global pharmaceutical giants.
- Regulatory delays and compliance burdens.
- Weak innovation ecosystem in universities and research institutions.
- Dependence on China for key APIs and raw materials.
Opportunities for India
- Expansion in biopharmaceuticals and biosimilars.
- Growth in contract research and manufacturing services (CRAMS).
- Development of new drug discovery platforms.
- Leveraging India’s strong IT and biotechnology capabilities.
Geopolitical and Strategic Implications
- Pharmaceutical leadership strengthens India’s soft power in global health diplomacy.
- Enhances supply chain resilience in global healthcare systems.
- Supports national security by ensuring drug self-reliance.
Way Forward
- Increase public and private investment in pharmaceutical R&D.
- Strengthen industry–academia collaboration for drug innovation.
- Develop domestic API manufacturing capacity.
- Simplify regulatory approval mechanisms.
- Encourage high-value innovation-driven pharmaceutical exports.
UPSC Relevance:
- GS Paper 3: Economy – pharmaceutical industry, innovation and manufacturing
- GS Paper 2: Governance – policy reforms in healthcare and innovation ecosystems